Other languages Anatara Lifesciences Ltd

Equities

ANR

AU000000ANR0

Delayed Australian S.E. Other stock markets 19:59:59 2024-05-05 EDT			5-day change	1st Jan Change
0.048 ^AUD	0.00%		-2.04%	+118.18%

05-01	Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	MT
04-09	Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Anatara Lifesciences Raises AU$1 Million via Shares Placement; Shares Decline 6%	04-30
Anatara Lifesciences Begins Recruitment for Irritable Bowel Syndrome Stage Two Trial	04-08
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2023	02-27
Anatara Lifesciences Ltd Announces Board Changes	23-10-01
Anatara Lifesciences to Proceed to Stage II of IBS Drug Trial	23-09-28
Anatara Lifesciences Ltd Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-23
Anatara Lifesciences Receives R&D Tax Rebate; Shares Up 3%	23-08-14
Anatara Lifesciences Provides Update on the Gastrointestinal Reprogramming(Garp) Trial for IBS	23-03-09
Anatara Lifesciences Ltd Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23
Anatara Lifesciences Ltd Announces board Changes	22-12-06
Anatara Lifesciences Raising Funds for Patient Trial, Future Project Acquisitions	22-10-21
Anatara Lifesciences Limited Provides Updates on 3FDC Clinical Trial	22-10-02
Anatara Lifesciences Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29
Anatara Lifesciences Modifies Protocol for Upccoming Gastrointestinal Disease Trial	22-08-11
Anatara Lifesciences Limited Appoints John Michailidis as Chief Operations Officer	22-06-21
Anatara Lifesciences Limited Announces to Provide an Update on the Progress of Clinical Trials in Irritable Bowel Syndrome and Psychological Functioning	22-06-21
Anatara Lifesciences Updates on Progress of Clinical Trials in Psychological Functioning and Irritable Bowel Syndrome, Diarrhoea Subtype	22-05-19
Anatara Lifesciences Limited Announces Chief Executive Officer Changes	22-05-04
Anatara Lifesciences Provides Clinical Trials Update	22-03-30
Anatara Lifesciences Limited Reports Earnings Results for the Half Year Ended December 31, 2021	22-02-23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Anatara Lifesciences Ltd

Equities

ANR

AU000000ANR0

Other languages

Filters